Clinical Trials

Inclusion Criteria

- Diagnosis of HCM consistent with current American College of Cardiology
Foundation/American Heart Association and European Society of Cardiology guidelines:
unexplained left-ventricular hypertrophy with non-dilated ventricular chambers in the
absence of other cardiac or systemic disease which can produce the required magnitude
of hypertrophy of a maximal left ventricular (LV) wall thickness ≥ 15 millimeters (mm)
(or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy [HCM]) as
determined by core laboratory interpretation.

- Peak left ventricular outflow tract (LVOT) pressure gradient < 30 millimeters mercury
(mm Hg) at rest and < 50 mm Hg with provocation (Valsalva maneuver and stress
echocardiography).

- New York Heart Association (NYHA) Class II or III.

Exclusion Criteria

- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics
non-obstructive hypertrophic cardiomyopathy (nHCM) such as Fabry disease, amyloidosis,
or Noonan syndrome with LV hypertrophy.

- History of unexplained syncope within 6 months prior to screening.

- History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior
to screening.

- Other protocol-defined Inclusion/Exclusion criteria apply.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/7/2024. Questions regarding updates should be directed to the study team contact.